quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:09:04·1382d
INSIDERFiling
Entasis Therapeutics Holdings Inc. logo

SEC Form 4: Ronsheim Matthew returned 150,000 shares to the company, closing all direct ownership in the company

ETTX· Entasis Therapeutics Holdings Inc.
Health Care
Original source

Companies

  • ETTX
    Entasis Therapeutics Holdings Inc.
    Health Care

Recent analyst ratings

  • Mar 8UpdateWedbush$1.80
  • Mar 4UpdateHC Wainwright & Co.$1.80
  • Oct 20UpdateBMO Capital$7.00
  • Oct 19UpdateHC Wainwright & Co.$6.00

Related

  • PR1289d
    Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
  • SEC1372d
    SEC Form 15-12G filed by Entasis Therapeutics Holdings Inc.
  • NEWS1379d
    Over $42 Million Bet On This Biotechnology Stock? 4 Penny Stocks Insiders are Buying
  • INSIDER1380d
    SEC Form 4: Innoviva, Inc. bought $42,395,047 worth of shares (19,270,476 units at $2.20)
  • SEC1381d
    SEC Form EFFECT filed by Entasis Therapeutics Holdings Inc.
  • SEC1381d
    SEC Form EFFECT filed by Entasis Therapeutics Holdings Inc.
  • SEC1381d
    SEC Form EFFECT filed by Entasis Therapeutics Holdings Inc.
  • SEC1381d
    SEC Form EFFECT filed by Entasis Therapeutics Holdings Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022